Radiation Therapy for Carcinoma, Non-Small-Cell Lung

[Incidence/yr and deaths/yr.] The incidence of lung carcinoma, not of histology, was significantly higher for women and for Asians/Pacific Islanders. A significantly higher rate of carcinoma death among African Americans was observed for whites compared to Chinese/Filipino and Japanese/Korean (p < 0.05). A lower rate of lung cancer death among Caucasian women was observed in the Hispanic/Latino group than in those of Japanese ethnic background (p = 0.02). Among Japanese/Korean women, the incidence ratio of lung carcinoma death was 3.0 times greater for current smokers.

The current study demonstrates that patients with non-small-cell lung cancer treated with chemotherapy are significantly more likely to be alive 10 years post surgery as compared to patients with non-small-cell lung cancer who did not receive chemotherapy. These data suggest that non-small-cell lung cancer can be cured in some patients.

Lung carcinoma, a type of cancer, is more common in men than women. The overall proportion is 11.1 per 1000 men, while only 1.8 per 1000 women. Tobacco use is also more common among men, at 60.4 per 1000 men. The 5-year survival rates in the USA are 74.0 in men and 59.7 in women. In the United Kingdom, the five-year survival is only 59.8 out of 100,000 in men and 54.7 per 100,000 women.

Carcinoma, non-small-cell lung was often treated with chemotherapy such as carboplatinum or cisplatin or targeted therapy such as erlotinib; however, some treatments such as radiation therapy/brachytherapy were less commonly used. Clinical trials were more common for breast cancer than for carcinoma, non-small-cell lung. Physicians usually discuss treatment with their patients, and patients often express treatment preferences.

Data from a recent study indicated that the main factors that contribute to the risk of developing carcinoma, non-small cell lung were old age at diagnosis and smoking. Data from a recent study may therefore have important implications in deciding which factors to target in primary and secondary prevention of non-small cell lung cancer.

Signs of cancer are not all specific to that particular type of cancer. Common signs include swelling/distension of the neck, neck lump, or, in cases of lung cancer, chest wall pain, which may result in weight loss. Tests such as CT scan, X-ray scan or MRI are other signs of carcinoma, non-small-cell lung.

These recent studies on cancer research, as reported to the journal OncoLink, had a significant impact on our patients with NSCLC. Thus, there is strong evidence that these studies will have a significant impact on the overall care of patients with NSCLC.

Quality of life is significantly improved in the first six months following RT for carcinoma, NSCLC. The majority of those who report improvement in quality of life are satisfied with the gains.

The overall 5-year survival rate in the United States was 31% for all lung cancers and 35% for small cell lung cancer and 11% for non-small cell lung cancer. Among the nonsmall cell lung cancers, the prognostic value of subgroup analyses remained significant.

For RT, the most common side effects in NSCLC patients are acute chest discomfort or shortness of breath, rash, loss of appetite, fatigue, nausea, dyspepsia or heartburn, coughs, and a headache. Patients with a history of asthma are more likely to develop acute bronchitis.

These data suggest that carcinoma, non-small-cell lung progresses through two distinct phases, an invasive invasive phase and a noninvasive metastatic phase, both of which are associated with different molecular changes.